ⓘ KRN23

                                     

ⓘ KRN23

KRN23 is an investigational human monoclonal IgG 1 antibody targeted against the phosphaturic hormone, fibroblast growth factor 23. Initially discovered by Kyowa Hakko Kirin, it is now being developed by Ultragenyx and is currently in Phase III clinical trials for the treatment of X-linked hypophosphatemia.

XLH is a genetic disease affecting the metabolism of phosphate in the body, which leads to hypophosphatemia. The disease is characterized by overproduction of the hormone FGF-23 in bone cells. In FGF-23 hormone responsible for blocking phosphate reabsorption in the kidney and suppresses vitamin D affects the absorption of phosphates in the intestine. Due to excessive activity of fgf23, phosphate levels in the blood are abnormally low, which affects the bone Constitution. Thus, KRN23 is intended to bind to the receptor of FGF23 and to inhibit excess activity of fgf23 hormone in the body.